The modified OVs were able to potentiate the capacity of HER2-redirected CAR T cells to eliminate multiple CD44v6+ cancer cell lines (human HNSCC line FaDu, human prostate cancer cell line PC-3, and human cervical cancer cell line SiHa). The gene discussed is ERBB2; the disease is prostate cancer.